{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-058749","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.738499+00:00","generated_at":"2026-06-15T03:54:01.673492+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Milestone Pharma Q1 operating loss $15M; etripamil NDA on track for Q3 2023","bullets":["Cash of $101M as of March 31, 2023; with $125M RTW financing, runway into mid-2025.","NDA submission for etripamil (PSVT) to FDA remains on track for Q3 2023.","Phase 2 ReVeRA trial (AFib-RVR) topline data expected H2 2023.","Appointed Seth H.Z. Fischer to Board of Directors in March 2023.","Operating loss of $15.0M in Q1 2023 vs. $14.0M in Q1 2022; R&D expense rose to $10.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-058749","json":"https://secwatch.observer/filing/0001104659-23-058749.json","markdown":"https://secwatch.observer/filing/0001104659-23-058749.md","text":"https://secwatch.observer/filing/0001104659-23-058749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/0001104659-23-058749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/tm2315317d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:54:01.673492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9943ade5560701064095bd5901deb0724723b620","claim":"Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023, which also provided a clinical and corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/0001104659-23-058749-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}